<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268214</url>
  </required_header>
  <id_info>
    <org_study_id>MB102-229</org_study_id>
    <secondary_id>2013-004674-97</secondary_id>
    <secondary_id>D1695C00006</secondary_id>
    <nct_id>NCT02268214</nct_id>
  </id_info>
  <brief_title>Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes</brief_title>
  <acronym>DEPICT 1</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and
      effective therapy to improve glycemic control in patients with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Classification: Safety, Efficacy and Pharmacokinetics/dynamics
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2014</start_date>
  <completion_date type="Actual">August 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 4, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adjusted Mean Change in HbA1c From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model[RMM]).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model[RMM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Percent Change in Body Weight From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model[RMM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model[RMM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) From Baseline at Week 24</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) &gt;= 0.5% and Without Severe Hypoglycemia Events</measure>
    <time_frame>From Baseline to Week 24</time_frame>
    <description>Subjects with HbA1c reduction from baseline to week 24 (LOCF) &gt;= 0.5% and without severe hypoglycemia events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">833</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm A: Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 5 mg tablet orally, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dapagliflozin 10 mg tablet orally, once daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Placebo for Dapagliflozin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet orally, once daily for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Arm A: Dapagliflozin</arm_group_label>
    <arm_group_label>Arm B: Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for dapagliflozin</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Arm C: Placebo for Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes mellitus (T1DM)

          -  Central laboratory C-peptide &lt; 0.7 ng/ml (0.23 nmol/L)

          -  Insulin use for at least 12 months per patient reported or medical records

          -  Method of insulin administration (MDI or CSII) must have been unchanged for at least 3
             months prior to screening

          -  Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior
             to screening

          -  If on MDI insulin administration, subject must be on ≥ 3x injections per day

          -  Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%

          -  Body mass index (BMI) ≥ 18.5 kg/m2

        Exclusion Criteria:

          -  History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young
             (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased
             beta cell capacity

          -  Taking metformin and/or thiazolidinediones within 2 months prior to screening

          -  Taking any antidiabetic medication (other than insulin), within 1 month prior to
             screening

             - Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly
             administration and within 1 month prior to screening for once or twice daily
             administration

          -  History of diabetes ketoacidosis requiring medical intervention within 1 month prior
             to screening

          -  History of hospital admission for glycemic control (either hyperglycemia or
             hypoglycemia) within 1 month prior to screening

          -  Frequent episodes of severe hypoglycemia (more than one episode requiring medical
             assistance, emergency care), and/or glucagon therapy administered by a third-party
             individual within 1 month prior to screening

          -  History of Addison's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Maria Langkilde</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <zip>91356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404-7596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Concord</city>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Daw Park</city>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg West</city>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newcastle</city>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southport</city>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wollongong</city>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Stefan/Stainz</city>
        <zip>8511</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Y 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Esbjerg</city>
        <zip>6700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Randers NØ</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besançon Cedex</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>SAINT HERBLAIN Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aßlar</city>
        <zip>35614</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Falkensee</city>
        <zip>14612</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich</city>
        <zip>80939</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Neuwied</city>
        <zip>56564</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldenburg</city>
        <zip>23758</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pohlheim</city>
        <zip>35415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schweinfurt</city>
        <zip>97421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sulzbach</city>
        <zip>92237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Witten</city>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baja</city>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1213</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Létavértes</city>
        <zip>4281</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>6726</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Safed</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>61480</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <zip>50141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Padowa</city>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ravenna</city>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sesto San Giovanni</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <zip>31237</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>44150</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridas</city>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <zip>6090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torreon</city>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <zip>45200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zapopan</city>
        <zip>45116</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>010825</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>020045</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dolj</city>
        <zip>200134</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galati</city>
        <zip>800098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <zip>700515</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Almeria</city>
        <zip>04001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uppsala</city>
        <zip>75185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Welwyn Garden City</city>
        <zip>AL7 4HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3676&amp;filename=MB102229-revprot2_1_15.08.17_Redacted.pdf</url>
    <description>MB102229_CSP</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Add on to insulin</keyword>
  <keyword>Oral Antidiabetic</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 11 November 2014. The last subject completed the 24-week short-term treatment period 04 January 2017. This study was conducted at 138 sites in 17 countries.</recruitment_details>
      <pre_assignment_details>833 participants were randomized to a treatment group. Of the 771 participants not randomized to a treatment group: 585 No longer met study criteria, 125 withdrew consent, 26 were lost to follow-up, and 35 did not continue for other reasons</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dapagliflozin 5 mg + Insulin</title>
          <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="P2">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="P3">
          <title>Placebo + Insulin</title>
          <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="277"/>
                <participants group_id="P2" count="296"/>
                <participants group_id="P3" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="253"/>
                <participants group_id="P2" count="273"/>
                <participants group_id="P3" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: It consists of all subjects who received at least one dose of double-blind study medication during the short-term double-blind treatment period.</population>
      <group_list>
        <group group_id="B1">
          <title>Dapagliflozin 5 mg + Insulin</title>
          <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="B2">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="B3">
          <title>Placebo + Insulin</title>
          <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="277"/>
            <count group_id="B2" value="296"/>
            <count group_id="B3" value="260"/>
            <count group_id="B4" value="833"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="13.94"/>
                    <measurement group_id="B2" value="43.4" spread="13.89"/>
                    <measurement group_id="B3" value="42.7" spread="13.57"/>
                    <measurement group_id="B4" value="42.7" spread="13.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="279"/>
                    <measurement group_id="B3" value="246"/>
                    <measurement group_id="B4" value="787"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 65 and 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="128"/>
                    <measurement group_id="B4" value="430"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adjusted Mean Change in HbA1c From Baseline at Week 24</title>
        <description>Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model[RMM]).</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in HbA1c From Baseline at Week 24</title>
          <description>Adjusted mean change from baseline in HbA1c at Week 24 (Repeated Measures Model[RMM]).</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>Percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.0537"/>
                    <measurement group_id="O2" value="-0.47" spread="0.0538"/>
                    <measurement group_id="O3" value="-0.03" spread="0.0540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0697</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0696</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24</title>
        <description>Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model[RMM])</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Percent Change in Total Daily Insulin Dose From Baseline at Week 24</title>
          <description>Adjusted mean change from baseline in Total Daily Insulin Dose at Week 24 (Repeated Measures Model[RMM])</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>IU</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.74" spread="1.4881"/>
                    <measurement group_id="O2" value="-12.16" spread="1.4326"/>
                    <measurement group_id="O3" value="1.16" spread="1.6593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.9555</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.56</ci_lower_limit>
            <ci_upper_limit>-4.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-13.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.8643</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.75</ci_lower_limit>
            <ci_upper_limit>-9.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Percent Change in Body Weight From Baseline at Week 24</title>
        <description>Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model[RMM])</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Percent Change in Body Weight From Baseline at Week 24</title>
          <description>Adjusted mean percent change from baseline in body weight at Week 24 (Repeated Measures Model[RMM])</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>Kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="0.2330"/>
                    <measurement group_id="O2" value="-3.67" spread="0.2299"/>
                    <measurement group_id="O3" value="0.05" spread="0.2407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3251</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.68</ci_lower_limit>
            <ci_upper_limit>-2.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.3213</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.34</ci_lower_limit>
            <ci_upper_limit>-3.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24</title>
        <description>Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model[RMM])</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in 24-hour Mean Continuous Glucose Monitoring Glucose From Baseline at Week 24</title>
          <description>Adjusted mean change in 24-hour mean Continuous Glucose Monitoring glucose from baseline at Week 24 (Repeated Measures Model[RMM])</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.28" spread="1.8862"/>
                    <measurement group_id="O2" value="-12.97" spread="1.9231"/>
                    <measurement group_id="O3" value="5.06" spread="1.9320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.34</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4859</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.22</ci_lower_limit>
            <ci_upper_limit>-10.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.03</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5050</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.95</ci_lower_limit>
            <ci_upper_limit>-13.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24</title>
        <description>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring MAGE From Baseline at Week 24</title>
          <description>Adjusted Mean Change in 24-hour Continuous Glucose Monitoring Mean Amplitude of Glucose Excursions (MAGE) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.92" spread="1.9915"/>
                    <measurement group_id="O2" value="-16.55" spread="2.0419"/>
                    <measurement group_id="O3" value="2.38" spread="2.0477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.30</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6273</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.46</ci_lower_limit>
            <ci_upper_limit>-12.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-18.93</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6482</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.13</ci_lower_limit>
            <ci_upper_limit>-13.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) From Baseline at Week 24</title>
        <description>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) From Baseline at Week 24</title>
          <description>Adjusted Mean Change in Percent 24-hour Continuous Glucose Monitoring Glucose &gt; 70 and &lt;= 180 (mg/dL) from Baseline at Week 24 (Repeated Measures Model[RMM])</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" spread="0.8824"/>
                    <measurement group_id="O2" value="8.52" spread="0.9000"/>
                    <measurement group_id="O3" value="-2.13" spread="0.9032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>9.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1611</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.83</ci_lower_limit>
            <ci_upper_limit>11.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>RMM</method>
            <method_desc>Repeated Measures Model</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.65</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1689</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.35</ci_lower_limit>
            <ci_upper_limit>12.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) &gt;= 0.5% and Without Severe Hypoglycemia Events</title>
        <description>Subjects with HbA1c reduction from baseline to week 24 (LOCF) &gt;= 0.5% and without severe hypoglycemia events</description>
        <time_frame>From Baseline to Week 24</time_frame>
        <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
        <group_list>
          <group group_id="O1">
            <title>Dapagliflozin 5 mg + Insulin</title>
            <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O2">
            <title>Dapagliflozin 10 mg + Insulin</title>
            <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Insulin</title>
            <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With HbA1c Reduction From Baseline to Week 24 (LOCF) &gt;= 0.5% and Without Severe Hypoglycemia Events</title>
          <description>Subjects with HbA1c reduction from baseline to week 24 (LOCF) &gt;= 0.5% and without severe hypoglycemia events</description>
          <population>All randomized subjects who took at least one dose of double-blind study medication during the short-term double-blind period. The first 55 randomized subjects will be excluded from the full analysis dataset due to the presence of a randomization system error.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="259"/>
                <count group_id="O3" value="260"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Responders</title>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1980</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>4.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.29</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1979</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.23</ci_lower_limit>
            <ci_upper_limit>4.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Onset on or after the first date of double-blind treatment and on or prior to the last day of double-blind treatment 24 weeks plus 4 days for non-serious adverse event; plus 30 days for serious adverse event.</time_frame>
      <desc>Participants were questioned at each study visit about the occurrence of any health problems and any examination conducted at a study visit was assessed in comparison to the status at study entry.</desc>
      <group_list>
        <group group_id="E1">
          <title>Dapagliflozin 5 mg + Insulin</title>
          <description>Dapagliflozin 5 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="E2">
          <title>Dapagliflozin 10 mg + Insulin</title>
          <description>Dapagliflozin 10 mg oral tablet once daily for 24 weeks + background insulin</description>
        </group>
        <group group_id="E3">
          <title>Placebo + Insulin</title>
          <description>Placebo oral tablet once daily for 24 weeks + background insulin</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Acid peptic disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Hepatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="296"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Ketosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="277"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Obstructive uropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="277"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="277"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="296"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="38" subjects_at_risk="277"/>
                <counts group_id="E2" events="42" subjects_affected="36" subjects_at_risk="296"/>
                <counts group_id="E3" events="47" subjects_affected="39" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="277"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="296"/>
                <counts group_id="E3" events="16" subjects_affected="11" subjects_at_risk="260"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="277"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="296"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="277"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="296"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="260"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an Investigator requests permission to publish data from this study any such publication is to be agreed with AstraZeneca (AZ) in advance. The investigator agrees to provide AZ as soon as possible with drafts of proposed publications. Unless otherwise agreed, AZ shall have a period of 60 days from receipt of the proposed final manuscript to review it and may within such time require that submission for publication of the manuscript be delayed in order for AZ to file patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anna Maria Langkilde</name_or_title>
      <organization>AstraZenenca</organization>
      <phone>+46 31 7761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

